
Hanmi Spurs New Immunotherapy Development Through Open Innovation
The Korea Biomedical Review reported that Hanmi Pharmaceutica is launching new development projects in the field of dual- and multi-antibody-based immunotherapy drugs through open innovation with external technologies. The company’s open innovation projects include a licensing-in deal for an antibody from Phanes Therapeutics’, a U.S. biopharmaceutical
Comments Off on Hanmi Spurs New Immunotherapy Development Through Open Innovation • Read this story »